The iSpecimen Marketplace solves this problem by using proprietary technology to bridge the gap between researchers and specimens. Accessing de-identified electronic medical record and laboratory data from across a network of participating partner organizations – including hospitals, labs, biobanks, blood centers and other healthcare institutions – iSpecimen’s technology aggregates a vast amount of information about individual specimens and the patients from whom they came into a single, harmonized view. Researchers can quickly and easily search this data using detailed patient, specimen, and compliance criteria and instantly view the availability and details of specimens that meet their specific needs. Contracting is likewise simplified and accelerated, as researchers and providers alike contract once with iSpecimen and gain access to all other organizations in the network.
“Providing specimens through the iSpecimen Marketplace generates value for us on multiple levels,” said Amer Abouhamze, MHA, Assistant Director of the CTSI Biorepository at the University of Florida. “It allows us to reach thousands of scientists who are in need of high-quality biospecimens, providing us with an excellent method to more easily fulfill our research mission. It allows us to ensure the utilization of biospecimens as quickly as possible after procurement, in order to accelerate translational research. And finally, it gives us insight into our own inventory as well as the whole iSpecimen partner network to bolster internal research programs within the university.”
As of today, nearly one million biobanked specimens, including biofluids, solid tissue, and cells, are available on the iSpecimen Marketplace from biorepositories taking part in the company’s vast and growing partner network. As part of a phased approach, iSpecimen will add millions of clinical remnants to the marketplace in the coming weeks as well as prospectively collected research-use-only samples1 before the end of the year. All research-use-only samples available through iSpecimen are collected with patient consent as required by federal law, as well as institutional review board (IRB) oversight. The technology manages specimen consent status as part of its capabilities.
Additional features of the iSpecimen Marketplace include automated fulfillment and procurement processes, offering a partner-facing web interface that directs specimen selection, packing, and shipping. Further, as a benefit of participation, iSpecimen partners can use the technology to gain insight into their own specimen availability as well as access specimens from across the network for their own internal research needs.
“A diverse and ready supply of biospecimens is critical to accelerating research,” said Christopher Ianelli, MD, PhD, Founder and Chief Executive Officer, iSpecimen. “New diagnostics and treatments will only be as precise as the research work behind it. Our job is to close the gap between the research and provider communities by matching highly refined specimen requests to organizations that can fulfill them. We’re like a Kayak.com for biospecimen research, making sure these critical connections are made.”
To watch a demo of the iSpecimen Marketplace click here.
Headquartered in Lexington, MA, iSpecimen is the marketplace for human biospecimens, providing researchers with the specimens they need from the patients they want. The privately held company has developed the iSpecimen Marketplace, an online platform connecting healthcare organizations that have access to patients and specimens with the scientists who need them. Proprietary, cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. Researchers easily and compliantly gain access to specimens to drive scientific discovery. Partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. And ultimately, healthcare advances for all. For more information about iSpecimen, please visit www.ispecimen.com.
1 Research-use-only samples are collected from consented patients specifically for research purposes, as opposed to clinical remnants which are leftover after clinical testing is complete.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ispecimen-unveils-online-marketplace-for-human-biospecimens-300472633.html